{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Random+Match&page=23",
    "query": {
      "intervention": "Random Match",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 5391,
    "total_pages": 540,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Random+Match&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Random+Match&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T23:29:46.747Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05881408",
      "title": "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "delandistrogene moxeparvovec",
          "type": "GENETIC"
        },
        {
          "name": "placebo",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 148,
      "start_date": "2023-05-31",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-25T23:29:46.747Z",
      "location_count": 14,
      "location_summary": "Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05881408"
    },
    {
      "nct_id": "NCT01475825",
      "title": "A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia",
        "Heterozygous Familial"
      ],
      "interventions": [
        {
          "name": "mipomersen sodium 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "mipomersen sodium 70 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kastle Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 309,
      "start_date": "2011-12",
      "completion_date": "2015-12-29",
      "has_results": true,
      "last_update_posted_date": "2019-03-26",
      "last_synced_at": "2026-10-25T23:29:46.747Z",
      "location_count": 20,
      "location_summary": "Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more",
      "locations": [
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Cooper City",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01475825"
    },
    {
      "nct_id": "NCT01568918",
      "title": "Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postoperative Urinary Retention"
      ],
      "interventions": [
        {
          "name": "Tamsulosin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2012-05",
      "completion_date": "2019-11-21",
      "has_results": true,
      "last_update_posted_date": "2024-05-30",
      "last_synced_at": "2026-10-25T23:29:46.747Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01568918"
    },
    {
      "nct_id": "NCT00428597",
      "title": "A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Islet Cell",
        "Carcinoma, Pancreas"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2007-06",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2010-10-11",
      "last_synced_at": "2026-10-25T23:29:46.747Z",
      "location_count": 14,
      "location_summary": "Aurora, Colorado • Iowa City, Iowa • Worcester, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "City of Saint Peters",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428597"
    },
    {
      "nct_id": "NCT03285308",
      "title": "A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroparesis",
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Relamorelin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 336,
      "start_date": "2017-09-29",
      "completion_date": "2020-07-08",
      "has_results": true,
      "last_update_posted_date": "2021-07-29",
      "last_synced_at": "2026-10-25T23:29:46.747Z",
      "location_count": 113,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 95 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03285308"
    },
    {
      "nct_id": "NCT01912391",
      "title": "Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Borderline Personality Disorder"
      ],
      "interventions": [
        {
          "name": "Selegiline",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Selegiline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mood and Anxiety Research, Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-10",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-10-08",
      "last_synced_at": "2026-10-25T23:29:46.747Z",
      "location_count": 1,
      "location_summary": "Fresno, California",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01912391"
    },
    {
      "nct_id": "NCT02792218",
      "title": "Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ofatumumab subcutaneous injection",
          "type": "DRUG"
        },
        {
          "name": "Teriflunomide-matching placebo capsules",
          "type": "DRUG"
        },
        {
          "name": "Teriflunomide capsule",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo of ofatumumab subcutaneous injections",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 930,
      "start_date": "2016-09-20",
      "completion_date": "2020-07-20",
      "has_results": true,
      "last_update_posted_date": "2021-10-01",
      "last_synced_at": "2026-10-25T23:29:46.747Z",
      "location_count": 56,
      "location_summary": "Phoenix, Arizona • Berkeley, California • Fullerton, California + 50 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02792218"
    },
    {
      "nct_id": "NCT03844191",
      "title": "A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Coronary Disease"
      ],
      "interventions": [
        {
          "name": "RUC-4 Compound",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CeleCor Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 44,
      "start_date": "2019-02-18",
      "completion_date": "2019-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-10-25T23:29:46.747Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03844191"
    },
    {
      "nct_id": "NCT01492374",
      "title": "Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "BMS-241027",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching BMS-241027",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2012-02",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2014-07-24",
      "last_synced_at": "2026-10-25T23:29:46.747Z",
      "location_count": 15,
      "location_summary": "Anaheim, California • Long Beach, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01492374"
    },
    {
      "nct_id": "NCT03817125",
      "title": "Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Placebo for antibiotic",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin pretreatment",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for SER-401",
          "type": "DRUG"
        },
        {
          "name": "SER-401",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Parker Institute for Cancer Immunotherapy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2019-01-28",
      "completion_date": "2022-03-04",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-10-25T23:29:46.747Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03817125"
    }
  ]
}